Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Zymeworks Inc.NASDAQ: ZYME
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue growth accelerates
Q3 FY2026 revenue of $256.46M rose 828.7% year over year, ahead of the +97.8% change in trailing-twelve-month revenue. Sequentially, it rose 5487.4% from the prior quarter. Over 3 fiscal years it compounded at -36.4% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $334.28M (+215.5%) for the fiscal year ending Dec 2026, a step up from the +38.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $256.46M+5487.4% QoQ
- Last fiscal yearDec 2025
- $105.97M+38.9% YoY
- LTMSep 2026
- $265.97M+97.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 105.97M USD
- Year-over-year change
- +38.9%
- 4-year CAGR
- +41.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.97M | +38.9% |
| FY2024 | 2024-12-31 | 76.3M | +0.4% |
| FY2023 | 2023-12-31 | 76.01M | -81.6% |
| FY2022 | 2022-12-31 | 412.48M | +1446.0% |
| FY2021 | 2021-12-31 | 26.68M | — |
Revenue vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 revenue of $265.97M is the 2nd highest of the 11 companies compared; the peer median is $54.1M.
- Its year-over-year change of +97.8% is the 3rd highest of 9, against a peer median of -16.5%.
- Over three fiscal years its annual growth of -36.4% compares with a peer median of +6.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Sep 2026 | $265.97M | +97.8% | -36.4% | |
| LTM Mar 2026 | $157.08M | +3.1% | -0.1% | |
| LTM Jun 2026 | $104.97M | -36.1% | -8.6% | |
| LTM Mar 2026 | $79.18M | +4.4% | -27.1% | |
| LTM Mar 2026 | $72.66M | +163.4% | +113.3% | |
| LTM Mar 2026 | $35.54M | -75.9% | +12.8% | |
| LTM Mar 2026 | $11.88M | — | +424.9% | |
| LTM Sep 2026 | $112K | -95.7% | -14.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding ZYME) | $54.1M | -16.5% | +6.3% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.